James Dentzer Insider Profile
4 Followers
James Dentzer, CFO at Dicerna Pharma, holds 0.00 shares in Dicerna Pharma (Ticker: DRNA), holds 148.73K shares in Curis (Ticker: CRIS), holds 3.32K shares in Imunon (Ticker: IMNN). Most recently, James Dentzer ― shares of Dicerna Pharma on ― for an estimated value of ―.
Profitable Transactions
1 out of 2 Profitable Transactions
Average Return
-233.80%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that James Dentzer holds in companies
Most Profitable Insider Trade
The most profitable trade made by James Dentzer
James Dentzer's Trading History
Dicerna Pharma
―
―
―
$0.00
Curis
Mar 23, 2026
President & CEO, Director
Uninformative Buy
―
$83.44K
Imunon
Aug 06, 2025
Director
Uninformative Buy
30.53K
$8.89K
Amicus
Oct 01, 2009
―
Uninformative Sell
1.93K
$464.77K
List of latest transactions for each holding click on a transaction to see James Dentzer's performance on stock
You May Also Like
James Dentzer insider profile FAQ
What is the percentage of profitable transactions made by James Dentzer?
The percentage of profitable transactions made by James Dentzer is 50%.
What is the average return per transaction made by James Dentzer?
The average return per transaction made by James Dentzer is -233.80%.
What stocks does James Dentzer hold?
James Dentzer holds: DRNA, CRIS, IMNN, FOLD stocks.
What was James Dentzer’s latest transaction?
James Dentzer latest transaction was an Uninformative Buy of ―.
What was James Dentzer's most profitable transaction?
James Dentzer’s most profitable transaction was an Informative Sell of CRIS stock on January 31, 2022. The return on the trade was 77.00%.
What is James Dentzer's role in Dicerna Pharma?
James Dentzer's role in Dicerna Pharma is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.